Healthcare sector peers ranked by AI committee score · Updated nightly
| Symbol | Company | Sector | Score | Rating | Mkt Cap | P/E | Beta | Compare |
|---|---|---|---|---|---|---|---|---|
| NVS | Novartis AG | Healthcare | 72.0 | Strong Buy | $300.4B | 24.0 | 0.46 | Compare |
| RVTY | Revvity | Healthcare | 70.8 | Strong Buy | $13.7B | 58.6 | 1.07 | Compare |
| INCY | Incyte | Healthcare | 70.4 | Strong Buy | $25.9B | 15.7 | 0.77 | Compare |
| ARQT | Arcutis Biotherapeutics, Inc. | Healthcare | 70.4 | Strong Buy | $3.1B | 112.2 | 1.53 | Compare |
| UTHR | United Therapeutics | Healthcare | 70.1 | Strong Buy | $21.8B | 17.0 | 0.56 | Compare |
| TMO | Thermo Fisher Scientific | Healthcare | 69.3 | Buy | $233.7B | 33.8 | 0.85 | Compare |
| CHE | Chemed Corp. | Healthcare | 69.2 | Buy | $7.1B | 27.2 | 0.51 | Compare |
| GMED | Globus Medical | Healthcare | 68.7 | Buy | $11.3B | 21.2 | 0.95 | Compare |
| CDNA | CareDx, Inc | Healthcare | 68.5 | Buy | $2.5B | 22.1 | 2.42 | Compare |
| NVST | Envista Holdings | Healthcare | 67.6 | Buy | $4.4B | 46.3 | 0.86 | Compare |
| WST | West Pharmaceutical Services | Healthcare | 67.6 | Buy | $24.9B | 44.9 | 1.14 | Compare |
| ONC | BeOne Medicines AG | Healthcare | 67.5 | Buy | $39.7B | 27.3 | 0.50 | Compare |
| IDXX | Idexx Laboratories | Healthcare | 67.2 | Buy | $44.1B | 39.3 | 1.54 | Compare |
| ARGX | argenx SE | Healthcare | 67.1 | Buy | $62.9B | 37.0 | -0.02 | Compare |
| EXEL | Exelixis | Healthcare | 67.1 | Buy | $13.7B | 16.6 | 0.42 | Compare |
| MEDP | Medpace | Healthcare | 66.8 | Buy | $17.3B | 35.7 | 1.15 | Compare |
| SYRE | Spyre Therapeutics, Inc. | Healthcare | 66.7 | Buy | $9.3B | -54.7 | 3.03 | Compare |
| UHS | Universal Health Services | Healthcare | 66.4 | Buy | $10.7B | 7.2 | 1.06 | Compare |
| ABT | Abbott Laboratories | Healthcare | 66.4 | Buy | $201.9B | 37.5 | 0.58 | Compare |
| SNY | Sanofi | Healthcare | 66.3 | Buy | $109.7B | 24.0 | 0.28 | Compare |
Why These Stocks?
These companies operate in the same Healthcare sector as DaVita. Rankings are based on the latest AI committee score. View DVA full analysis →